JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rice, A J
Right arrow Articles by Quinn, C M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rice, A J
Right arrow Articles by Quinn, C M
Journal of Clinical Pathology 2002;55:921-925
© 2002 Journal of Clinical Pathology


ORIGINAL ARTICLE

Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast

A J Rice1, M A Steward2, C M Quinn3

1 Department of Histopathology, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK
2 Department of Surgery, Christie Hospital, Wilmslow Road, Withington, Manchester M20 9BX, UK
3 Irish National Screening Programme and Department of Histopathology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

Correspondence to:
Dr A Rice, Department of Histopathology, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK;
ricealex{at}hotmail.com Aim: Angiogenesis plays an important role in tumour growth and has been shown to occur around both in situ and invasive tumours. The degree of angiogenesis within tumours depends on the balance of pro-angiogenic and anti-angiogenic factors. One such anti-angiogenic factor is thrombospondin 1 (TSP-1). This study investigates the pattern of expression of TSP-1 in ductal carcinoma in situ (DCIS) of the breast and its relation to the surrounding microvessel pattern and density.

Materials/Methods: The expression of TSP-1 was studied in formalin fixed, paraffin wax embedded sections from 58 cases of pure DCIS, using a monoclonal antibody against TSP-1 and the avidin–biotin–diaminobenzidine immunoperoxidase detection system. Vessels were stained with a monoclonal antibody to the endothelial cell marker CD31. Stromal microvessel density was assessed by counting "hot spots" within 500 µm of the basement membrane of involved ducts using a 25 point Chalkey graticule.

Results: TSP-1 staining of the basement membrane around duct spaces with DCIS was seen in 69% of cases. In addition, staining of the stroma between involved duct spaces was seen in 31% of cases, with a fibrillary pattern identical to that seen in invasive breast carcinomas. In 12% of cases no staining for TSP-1 was seen. Two patterns of vascularity were identified. A cuff of vessels immediately adjacent to the basement membrane of ducts with DCIS was seen in 71% of cases. The presence of stromal TSP-1 was significantly associated with DCIS showing no/little necrosis (p = 0.01) and no/little periductal inflammation (p = 0.04). There was a trend between the presence of stromal TSP-1 and tumour cell negativity for p53 (p = 0.087). The stromal microvessel Chalkey point count ranged between 3.33 and 16. An increased stromal microvessel count was associated with high histological grade (p = 0.02), extensive necrosis (p = 0.047), and pronounced periductal inflammation (p = 0.049). There was no association between the presence of stromal TSP-1 and stromal microvessel density.

Conclusions: TSP-1 is expressed in the stroma around DCIS and in the immediately adjacent basement membrane. Expression of stromal TSP-1 is lost in DCIS with more aggressive histological features. The absence of a relation with microvessel density suggests that other angiogenic factors may play an important role in DCIS.


Keywords: breast; ductal carcinoma in situ; angiogenesis; thrombospondin

Abbreviations: bFGF, basic fibroblast growth factor; DCIS, ductal carcinoma in situ; Hif-1{alpha}, hypoxia inducible factor 1{alpha}; TBS, Tris buffered saline; TGF-ß, transforming growth factor ß; TSP-1, thrombospondin 1; VEGF, vascular endothelial growth factor




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. S. Levenson, K. E. Thurn, L. A. Simons, D. Veliceasa, J. Jarrett, C. Osipo, V. C. Jordan, O. V. Volpert, R. L. Satcher Jr., and R. B. Gartenhaus
MCT-1 Oncogene Contributes to Increased In vivo Tumorigenicity of MCF7 Cells by Promotion of Angiogenesis and Inhibition of Apoptosis
Cancer Res., December 1, 2005; 65(23): 10651 - 10656.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. P. Manna and W. A. Frazier
CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A
Cancer Res., February 1, 2004; 64(3): 1026 - 1036.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.